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Tuberculosis (TB) and HIV alter the immune system, and coinfected (HIV-TB) indivi-
duals usually present deregulations of T-lymphocytic immune response. We previously 
observed an increased frequency of “unconventional” CD4+CD25−FoxP3+ Treg (uTreg) 
population during HIV-TB disease. Therefore, we aimed to explore the phenotype and 
function of uTreg and conventional CD4+CD25+FoxP3+ Treg subsets (cTreg) in this 
context. We evaluated the expression of CD39, programmed cell death protein 1 (PD1), 
glucocorticoid-induced tumor necrosis factor receptor (GITR), and the effector/memory 
distribution by flow cytometry in cTreg and uTreg. Also, IL-10, TGF-β, IFN-γ production, 
and the suppressor capacity of uTregs were analyzed in cocultures with effector lympho-
cytes and compared with the effect of regulatory T cells (Tregs). We found diminished 
expression of CD39 and higher levels of PD1 on uTreg compared to cTreg in both HIV-TB 
and healthy donors (HD). In addition, uTreg and cTreg showed differences in maturation 
status in both HIV-TB and HD groups, due to the expansion of effector memory uTregs. 
Interestingly, both HIV-TB and HD showed a pronounced production of IFN-γ in uTreg 
population, though no significant differences were observed for IL-10 and TGF-β pro-
duction between uTreg and cTreg. Moreover, IFN-γ+ cells were restricted to the CD39− 
uTreg population. Finally, when the suppressor capacity was evaluated, both uTreg and 
cTreg inhibited polyclonal T cell-proliferation and IFN-γ production in a similar extent. 
These findings suggest that uTregs, which are expanded during HIV-TB coinfection, 
exert regulatory functions in a similar way to cTregs despite an altered surface expression 
of Treg characteristic markers and differences in cytokine production.
Keywords: human, infectious immunity bacteria, regulatory mechanisms, cytokines, effector/memory 
Treg populations
Abbreviations: TB, tuberculosis; LTB, latent TB infection; uTreg, unconventional regulatory T lymphocyte; cTreg, conven-
tional regulatory T lymphocyte.
TaBle 1 | epidemiological characteristics of the subjects enrolled.
hiV-TB hiV-lTB hiV healthy donors
Number of subjects enrolled 28 18 17 19
Median age in years (IQR) 39 (33–44) 35 (29–40) 35 (28–47) 37 (29–43)
Female/male distribution 10/18 8/10 6/11 12/17
HIV status + + + −
Median CD4 count (IQR) 129 (81–271) 386 (297–575) 307 (162–523) 834 (570–12,923)
Median viral load (IQR) 28,771 (89–93,136) 10,195 (124–16,742) 12,934 (1,055–21,400) N/A
IQR, interquartile range.
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inTrODUcTiOn
Tuberculosis (TB) remains to be a serious threat, especially in 
HIV patients. In fact, Mycobacterium tuberculosis (Mtb) is the 
most common cause of AIDS-related deaths, and HIV is the 
most powerful known risk factor predisposing for TB infection 
and progression to active disease (1). Both pathogens synergisti-
cally alter the immune system and accelerate the deterioration 
of immunological functions. Besides the risk for the infected 
individuals, HIV-TB coinfection leads to a huge burden over 
health-care systems, especially in resource-limited countries (2).
It is well known that regulatory T cells (Tregs) play a central 
role in the induction and maintenance of tolerance mechanisms. 
Deficiencies in this cell population can lead to autoimmune pro-
cesses or to a poor response to pathogens (3). This Treg subset 
is characterized by high expression of CD25 (the alpha chain 
of the IL-2 receptor), but until now the most specific marker 
for this population is the forkhead box P3 (FoxP3) transcrip-
tion factor, whose expression is critical for a proper suppres-
sor function. Accordingly, the best known suppressor T  cell 
population is defined as CD4+CD25+FoxP3+, or “conventional” 
Tregs (cTreg). Nevertheless, Tregs engulf several subpopulations 
with different functional capacities (4). Besides, an enhanced 
expression of FoxP3 in human activated T lymphocytes has been 
observed without conferring any regulatory properties to this 
cell population (5).
HIV-TB coinfection sets up a complex scenario, where the 
immune activation induced by both pathogens accelerates a 
decline in immune functions, leading to death if untreated (2). In 
this context, the expansion of FoxP3+ Tregs is a discouraging fea-
ture, as this leads to the suppression of antigen-specific immune 
responses, including those specific for M. tuberculosis (6). We 
previously reported a unique population of CD4+CD25−FoxP3+ 
T lymphocytes that was expanded in a cohort of HIV-TB coin-
fected patients, a population we defined as “unconventional” 
Tregs (uTreg) (7). This unique subset was also described in 
the context of systemic lupus erythematosus (SLE), but not in 
other autoimmune disorders, such as rheumatoid arthritis (8). 
Moreover, the nature of these uTreg lymphocytes is controversial, 
since some authors propose that these cells encompass immature 
regulatory cells, while others suggest that uTregs are effector 
CD4+ T  cells with a transient expression of FoxP3 because of 
T cell activation (9).
The role of Tregs in TB has been widely studied over the past 
years, yet some gaps need further research. In this scenario, Treg 
heterogeneity has not been deeply investigated, although previous 
studies indicate the existence of functionally diverse populations 
(10). Remarkably, surface and intracellular expression of certain 
molecules also determine cell functions. For instance, CD39 
expression will define a more pronounced inhibitory profile for 
Tregs, determining the shape of the immune response to Mtb 
infection (11). Additionally, programmed cell death protein 1 
(PD1) expression will also define Treg function and exhaustion as 
described in TB patients (12). Finally, the memory/effector char-
acterization might define T cell memory pools, which exert dif-
ferent suppressor capacities among distinct Treg subpopulations. 
For instance, Mailloux et al. have demonstrated that peripheral 
effector memory (EM) Tregs in healthy donors (HD) constitute 
only 2% of all Tregs but when isolated they exhibit greater in vitro 
suppressor activity compared to central memory (CM) or naïve 
(N) cells (13).
Thus, we aimed to explore the nature of “unconventional” Tregs, 
unraveling their phenotype and inhibitory capacity to get a 
better understanding of the pathogenic mechanisms involved in 
M. tuberculosis immune response in the context of HIV infection. 
We could observe some unique features in these uTregs, but still 
they maintained their inhibitory capacity as they suppressed both 
proliferation and cytokine production from effector T cells in an 
in vitro setting.
MaTerials anD MeThODs
individuals enrolled
The present cross-sectional study recruited the following popu-
la tion (Table  1): 1. HIV-1 infected patients with active TB 
(HIV-TB) who received anti-TB therapy for less than 1 week, 2. 
Asymptomatic HIV-1 infected patients (HIV+) as determined by 
ELISA and confirmatory Western Blot who were tuberculin skin 
test negative (TSTneg), 3. HIV-1 infected individuals latently 
infected with Mtb (HIV-LTB), 4. HD TSTneg. All individuals were 
Bacillus Calmette–Guérin vaccinated and evaluated at Hospital 
J. A. Fernandez, Buenos Aires. Some HIV-1 infected individuals 
were under antiretroviral treatment following local and interna-
tional guidelines. None of the recruited individuals presented 
associated infections, neither autoimmune nor endocrine imbal-
ance. The Ethics Committees from Fundación Huésped and from 
the University of Buenos Aires School of Medicine approved the 
current study. In addition, written informed consent was docu-
mented from all study subjects.
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cell Preparations and culture conditions
PBMCs were isolated by density gradient centrifugation on 
Ficoll–Hypaque and cultured at 2  ×  106/ml with PMA and 
ionomycin (5 and 500 ng/ml, respectively, Sigma-Aldrich) and 
brefeldin A (3  µg/ml, Sigma-Aldrich) in RPMI 1640 medium 
(Sigma-Aldrich) supplemented with 10% fetal calf serum (PAA), 
2  mM l-glutamine (Gibco BRL), 100  U/ml penicillin (Gibco 
BRL), and 100 µg/ml streptomycin (Gibco BRL) at 37°C for 6 h. 
Then, cells were washed, stained for surface and intracellular 
markers, and analyzed by flow cytometry (see below).
Flow cytometry
PBMCs (1 × 106) were stained with CD4 PerCP, CD25 Alexa488, 
and FoxP3 PE for the identification of Treg populations (BD FoxP3 
staining protocol, according to the manufacturer’s instructions). 
CD4 PerCP, CD25 Alexa488, CD27 APC, and CD45RA PE-Cy7 
(eBioscience) were used to assess surface phenotype. In some 
experiments, CD39 APC, PD1 PE-Cy7, and glucocorticoid-
induced tumor necrosis factor receptor (GITR) APC (Biolegend) 
were analyzed on Treg populations. Intracellular cytokine stain-
ing was performed to determine IFN-γ and IL-10 production 
at the single-cell level as described previously using anti-human 
IFN-γ-PE-Cy7 and anti-human IL-10 APC (both from 
Biolegend). For the evaluation of TGF-β secretion, the surface 
expression of the latency-associated peptide (LAP) protein 
(anti-human LAP-PE-Cy7, Biolegend) was assessed. For all 
flow cytometry experiments, sample acquisition and analysis 
were carried out on a FACSCanto flow cytometer using the BD 
FACSDiva software (BD Biosciences). Negative control samples 
were incubated with irrelevant, isotype-matched mAbs in paral-
lel with experimental samples.
Functional assays
Treg Isolation
Due to the limitations of FoxP3 to separate human Tregs for func-
tional studies, we first developed a phenotyping strategy based on 
the expression of CD39 surface marker as a surrogate of FoxP3 
for subsequent FACS sorting experiments. This strategy allowed 
us to obtain three specific populations: CD4+C25+CD39+ (cTreg), 
CD4+CD25−CD39+ (uTreg), and CD4+CD25−CD39− [effector 
(Eff)]. These T cell subpopulations were isolated from HD samples 
by flow cytometry cell sorting on a FACSAria (BD Biosciences). 
PBMCs were stained with mAb against CD4 PerCP, CD25 Alexa 
488, and CD39 APC for 20 min at 4°C. Sort gates were additionally 
restricted to a lymphocyte gate as determined by typical forward 
and side scatter characteristics. Then, CD4+CD25+CD39+ (cTreg), 
CD4+CD25−CD39+ (uTreg), and CD4+CD25−CD39− (Eff) T cells 
were enriched. In parallel, samples were labeled for CD4, CD25, 
CD39, and FoxP3 to determine the percentage of FoxP3-positive 
cells in the sorted subpopulation.
Suppression Assays
For the assessment of maximum T cell proliferation, FACS-sorted 
CD4+CD25−CD39− (effector T cells) from HD were stimulated in 
U-bottom 96-well plates with soluble anti-CD3 mAb (10 ng/ml) 
and allogenic PBMC (1  ×  105) pretreated with mitomicin 
(25 µg/ml, Sigma-Aldrich) as feeder cells. Additionally, suppres-
sion was determined by coculturing 2.5 × 104 CD4+CD25−CD39− 
(Eff) T cells in the presence of FACS-sorted CD4+CD25−CD39+ 
(uTregs) or CD4+CD25+CD39+ (cTregs) T cells at 1:1, 1:2, 1:4, 
1:8, 1:16, 1:32 Treg:Eff ratios in RPMI 1640 plus 10% FCS at 37°C 
in a humidified CO2 containing atmosphere. T cell proliferation 
was assessed at day 5 by measuring [methyl-3H] thymidine 
(1 μCi per well, GE Healthcare) incorporation. The proliferative 
response of stimulated CD4+CD25−CD39− effector T cells in the 
absence of CD4+CD25−CD39+ or CD4+CD25+CD39+ Tregs was 
defined as 100%. Background proliferation was determined from 
cultures of unstimulated CD4+CD25−CD39− effector T  cells. 
Cell-free supernatants were collected on day 4 of culture previ-
ous to [methyl-3H] thymidine addition and analyzed for cytokine 
concentrations by ELISA.
statistical analysis
Statistical analyses were conducted using GraphPad Prism 5 ver-
sion 5.04. Comparisons between two groups were evaluated by 
the Wilcoxon test or Mann–Whitney test for paired or unpaired 
samples, respectively. Comparisons between three or more 
groups were done using the Kruskal–Wallis analysis of variance 
followed by post hoc comparisons (Dunns), when applicable. For 
paired samples, Friedmand test was performed. Correlations were 
determined using the Spearman’s rank test. Statistical analysis 
and display of multicomponent distributions were performed 
by partial permutation test using SPICE v5.1 (http://exon.niaid.
nih.gov/spice/) (14). For all comparisons, a p value <0.05 was 
considered significant.
resUlTs
expansion of Unconventional  
cD25-negative Treg Population  
in hiV-TB Patients
We previously showed that HIV-TB patients present an 
increased frequency of an “unconventional” regulatory T  cell 
population (uTreg), defined as CD25−FoxP3+CD4+ T cells (7). 
This unique population was first described in the context of SLE 
(8, 9, 15). Therefore, we performed a detailed phenotypic analysis 
of this particular population in a large number of patients. In 
contrast to “conventional” CD25+FoxP3+CD4+ Treg (cTreg), 
which exhibited similar frequencies in HIV-TB coinfected 
patients, HIV+ individuals latently infected with TB (HIV-TBL), 
HIV+ persons, and HD (Figure  1A), uTreg frequencies were 
significantly higher in HIV-TB than HD (Figure  1B) similar 
to our previous results (7). Even though we did not observe 
any significant differences between HIV-TB and HIV-TBL 
or HIV, the last two groups showed similar frequencies to 
those seen in the HD group (Figure  1B). Additionally, we 
observed a diminished expression of FoxP3 per cell—in terms 
of mean fluorescence intensity—in uTreg compared to cTreg 
in both HIV-TB and HD individuals (p <  0.01, Figure  1C), 
suggesting a reduced suppressor capacity in uTreg compared 
with cTreg, as described previously (9). Moreover, since the 
ab solute number of CD4+ T cells of infected patients negatively 
FigUre 1 | analysis of cTreg and uTreg populations across the spectrum of tuberculosis (TB) infection. PBMC from HIV-TB, HIV-LTB, HIV+, and healthy 
donors (HD) individuals were stained for cell surface expression of CD4, CD25, CD39, glucocorticoid-induced tumor necrosis factor receptor (GITR), programmed 
cell death protein 1 (PD1), CD45RA, CD27, and intracellular FoxP3 and analyzed by flow cytometry. Cells were gated based first on the basis of CD4 expression, 
then CD4+ cells were analyzed for the expression of CD25 and FoxP3 in order to define “conventional” and “unconventional” regulatory T cells (Tregs), and finally  
the expression of CD45RA/CD27 was determined in uTregs and cTregs. (a) Evaluation of the percentage of cTreg population in HIV-TB, HIV-LTB, HIV+, and HD.  
(B) Comparison of the percentage of uTreg between groups. (c) Mean fluorescence intensity (MFI) of FoxP3 was measured to compare the level of expression of 
this molecule in uTreg and cTreg of HIV-TB and HD. Wilcoxon test was used for statistical comparison between the two different subsets. (D) Correlation analysis 
between the absolute number of CD4+ T cells and the percentage of uTreg from HIV-infected patients (HIV-TB, HIV-LTB, and HIV). (e) The expression of CD27  
and CD45RA on CD4+ T cells from HIV-TB, HIV-LTB, HIV+, and HD patients was analyzed by flow cytometry; (top) pie charts summarize the data and each slice 
corresponds to the mean proportion of uTreg cells for each phenotype. (Bottom) Possible phenotypes are shown on the x-axis whereas percentages of distinct 
T-cell subsets within uTreg cells are shown on the y-axis. (F) Representative dot plots of Treg identification, maturation status distribution and surface CD39, PD1, 
and GITR expression. For the comparison between the four groups, Kruskal–Wallis test was performed followed by Dunns posttest. Horizontal lines represent the 
median range and each point represents an individual subject; asterisks indicate a significant difference between groups; *p < 0.05; **p < 0.01; ***p < 0.001. 
Spearman test was performed to evaluate correlations between variables. Comparisons of phenotype distribution were performed using the partial permutation  
test as described in Ref. (14) and the Kruskal–Wallis test followed by Dunn’s multiple comparisons posttest.
4
Angerami et al. Treg Differentiation in HIV-TB
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 528
correlated with the percentage of uTreg, the expansion of this cell 
subset could be related with the immune status of the patient 
(Figure 1D).
Suppressor Treg capacity may rely on specific TCR-dependent 
activation (16), suggesting that Tregs, similar to conventional 
effector T cells, modify their phenotype as they activate or expand. 
To explore this issue, peripheral uTregs were phenotypically 
discriminated in terms of CD27/CD45RA expression by flow 
cytometry as naïve (TregN), central memory (TregCM), effector 
memory (TregEM), and terminal effector (TregTE) Tregs as described 
elsewhere (13). Thus, partial permutation test (14) evin ced dis-
similar memory/effector distribution when comparing HIV-TB 
FigUre 2 | anti-TB treatment induces changes in uTreg but not in cTreg populations in hiV-TB patients. (a) Evaluation of uTreg (CD4+CD25–FoxP3+),  
(B) cTreg (CD4+CD25+FoxP3+) frequencies by flow cytometry, (c) C-reactive protein (CRP) plasma concentrations, (D) CD4+ lymphocytes count, and (e) HIV RNA 
copies per milliliter in peripheral blood from HIV-TB individuals along anti-TB treatment (0, 3, and 6 months); values obtained from healthy donors (HD) were used  
as controls. Friedman test for paired samples was used for comparisons between consecutive visits for each population, cTreg and uTreg (**p < 0.01; *p < 0.05). 
For comparison between each visit and values in HD group, Mann–Whitney test was performed (#p < 0.05 was consider significant). (F) Correlation analysis 
between the % of cTreg and the % of PD1+CD4+ T lymphocytes (left) and between the % of uTreg and the % of PD1+CD4 T cells (right) from HIV-TB individuals. 
Spearman rank test was used for the evaluation of the correlation. (g) Correlation analysis between the % of uTreg and the % of CD4+ TCM lymphocytes  
(upper panel) and between the % of uTreg and the % of CD4+ TEM cells (lower panel) from HIV-TB individuals. Spearman rank test was used to test correlation.
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to HD or HIV-LTB individuals (Figure 1E, pies and Figure 1F). 
These differences where due to augmented uTregCM proportions 
in HIV-TB patients compared to HIV-LTB and HD, diminished 
percentages of uTregN among HIV-TB versus HIV-LTB and HD, 
and also augmented proportions of HIV-TB uTregEM compared 
to both HIV+ and HD persons (Figure 1E, bars and Figure 1F). 
Consistent with these observations, we noticed that cTregs from 
HIV-TB patients depicted lesser cTregN proportions compared to 
both HIV-LTB and HD and higher percentages of cTregEM cells 
compared to HD (Figure S1 in Supplementary Material). These 
results suggest that coinfection could induce a bias of both uTregs 
and cTregs to a more differentiated effector profile, leading to a 
greater suppression activity as shown by others for TregEM from 
HD (13).
uTreg expansion is related to 
inflammation and cD4+ T cell 
Differentiation status
It has been shown that Treg frequency is restored to normal 
values after infection treatment (17). Accordingly, we assessed 
the proportion of uTreg and cTreg cells during TB treatment at 
a 3-month period intervals. In parallel, we determined plasma 
C-reactive protein (CRP) concentrations in the same samples in 
order to determine whether changes in inflammation levels could 
escort Treg changes after a 6-month period of antitubercular 
treatment. We therefore observed a gradual reduction in uTreg 
proportions with antitubercular treatment, reaching normal lev-
els after 6 months (Figure 2A). On the other hand, cTregs did not 
6Angerami et al. Treg Differentiation in HIV-TB
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depict any change during TB treatment (Figure 2B). As expected, 
the changes observed in uTreg percentages were accompanied by 
a gradual normalization of CRP plasma levels (Figure 2C). These 
data support the idea of TB as the cause of uTreg expansion in 
the context of coinfection with HIV, since this population was not 
expanded neither in HIV+ nor TB individuals (data not shown). 
As the reduction in HIV RNA plasma viral load (VL) accompa-
nied the normalization of uTreg proportions (Figure 2D) without 
CD4 count changes along treatment in our cohort (Figure 2E), it 
could be hypothesized that VL and its associated immune activa-
tion are driving the expansion of this subset. In this regard, we 
did not find any differences between groups when analyzing VL 
(Table 1), and also we did not observe any correlation between 
VL and uTregs percentages (Spearman r: 0.2497, p =  0.2091, 
n = 27 for HIV-TB individuals) suggesting that HIV-associated 
inflammation is not the driving force of uTreg expansion in 
HIV-TB coinfected patients. By contrast, when analyzing Treg 
proportions relative to CD4+ T cell activation (assessed as surface 
PD1 expression) we could observe a positive correlation between 
both uTregs and cTregs and PD1+CD4+ T  cells from HIV-TB 
patients (Figure 2F). Also the maturation status of CD4+ T cells 
correlated with uTreg proportions, since CM CD4+ T  cells 
positively correlated with uTreg proportions, whereas EM CD4+ 
T cells negatively correlated with uTregs in HIV-TB individuals 
(Figure 2G), but not in HIV+ or HIV-LTB individuals (data not 
shown). Overall, these data suggest that uTreg expansion is asso-
ciated with lymphocyte activation and CM differentiation of CD4 
T cells in HIV-TB coinfected individuals, whereas this expansion 
is independent of HIV RNA plasma VL.
Phenotypic characterization of Treg 
Populations in hiV-TB individuals
Previously, other authors have hypothesized that CD25−FoxP3+ 
CD4+ T cell population in SLE could encompass Tregs without 
CD25 expression or, contrary, activated effector T  cells with 
a transient FoxP3 expression (15). To address this issue, we 
performed a comparative phenotypic analysis between cTregs 
and uTregs by evaluating the ex vivo expression of the surface 
molecules CD39, PD1, GITR, and CD127, since they had been 
associated with regulatory function in Tregs (3, 8, 13, 18, 19). An 
increase in CD39 expression in HIV-TB and HIV+ individuals 
was observed compared to HD for both uTreg (Figure 3A) and 
cTreg (Figure S1 in Supplementary Material). Accordingly, PD1 
proportions increased in peripheral uTreg from HIV-TB and 
HIV patients compared to HD (Figure 3B) and also in cTreg from 
HIV-TB compared to HD (Figure S1 in Supplementary Material). 
Finally, GITR expression in uTregs did not differ between groups 
(Figure 3C) but HIV-TB patients depicted higher frequencies of 
GITR+ cTregs compared to HIV+ and HD individuals (Figure S1 in 
Supplementary Material). Continuing our analysis, we observed 
that CD39 expression was diminished on uTregs compared to 
cTregs both in HIV-TB and HD groups (p < 0.01, Figure 3A). 
Interestingly, PD1 expression was increased on uTregs compared 
to cTregs from all study groups (p < 0.05, Figure 3B), therefore 
suggesting an exhausted phenotype for uTregs irrespective of 
the individual’s condition. When analyzing GITR expression, 
we observed significantly increased proportions of this molecule 
in uTregs compared to cTregs from the same individuals in 
both HIV-TB and HIV-LTB (p <  0.05, Figure  3C), suggesting 
a Mtb-driven modulation of this molecule. By contrast, we did 
not observe any difference on CD127 expression between Treg 
populations (Figure S3 in Supplementary Material). Overall, 
these results indicate that HIV-TB coinfection induces pheno-
typical changes and a diminished regulatory capacity of uTregs 
compared to cTregs based on the lower expression of CD39 
and higher levels of PD1, the latter usually associated with an 
exhausted phenotype (20).
We then compared the memory/effector phenotype between 
uTreg and cTreg populations in the four study groups, based on 
the surface expression of CD27 and CD45RA as stated above. 
Partial permutation test evinced differences between memory/
effector distributions between uTreg and cTreg in HIV-TB, HD, 
and HIV-LTB individuals (Figure 4; Figure S2 in Supplementary 
Material, pies), due to increased proportions of EM uTreg in the 
infected groups. Additionally, increased percentages of terminal 
effectors and diminished proportions of CM were observed in 
uTreg compared to cTreg in HD (Figure 4). Finally, HIV individu-
als showed similar memory/effector phenotypes between uTreg 
and cTreg populations (Figure S2 in Supplementary Material). 
These data suggest a more differentiated phenotype for uTregs 
than cTregs, irrespective of the individuals’ infection status.
Differences in circulating effector/memory subset proportions 
may occur due to variations in their differentiation path (13). We 
therefore evaluated transitions between effector and memory 
populations by analyzing correlations between subset propor-
tions as described previously (13, 21). Thus, a negative correlation 
between the percentages of two given populations suggests that 
transitions between those subsets are prone to occur. By doing 
these analyses, we observed a strong negative correlation between 
CM and EM subsets proportions for both uTreg and cTreg from 
HIV-TB individuals (Figures 5A,C). Remarkably, these correla-
tions were not evident for the other groups (Figures 5B,D for HD 
and data not shown for HIV-LTB and HIV individuals). These 
results suggest the occurrence of a distinct differentiation path 
induced by Mtb and/or HIV over Treg lymphocytes in coinfected 
individuals that may account for the increment in uTregEM and 
cTregEM proportions observed.
Functional analysis of Treg Populations  
in hiV-TB individuals
Human Tregs have the potential of secreting a plethora of 
cytokines (i.e., IL-10, TGF-β, IL-17, IFN-γ among others) (10). 
Therefore, we sought to investigate the functional potential of 
cTregs and uTregs in order to better define the nature of uTregs. 
We initially stimulated PBMC from HIV-TB and HD individuals 
in the presence of PMA and ionomycin; then we assessed IL-10 
and IFN-γ production and LAP expression—a component of 
TGF-β prior to secretion by the cell—on Tregs by flow cytom-
etry. We then observed a similar capacity of IL-10 secretion and 
LAP expression for uTregs and cTregs, both in HIV-TB and HD 
(Figures  6A–D,H). Also, similar levels of both cytokines and 
peptide expression were detected when comparing HIV-TBs 
FigUre 3 | uTreg differ in cD39, programmed cell death protein 1 (PD1) and glucocorticoid-induced tumor necrosis factor receptor (giTr) 
expression levels with cTreg population. Comparison of the (a) CD39, (B) PD1, and (c) GITR expression between uTreg and cTreg from HIV-TB, HIV-LTB,  
HIV, and healthy donors (HD) individuals. Wilcoxon rank test was used for paired statistical analysis. For the comparison between the four groups, Kruskal–Wallis 
test was performed followed by Dunns posttest. *p < 0.05; **p < 0.01; ***p < 0.001; ##p < 0.01; ###p < 0.001.
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cTregs versus HDs cTregs (not shown). Surprisingly, when com-
paring IFN-γ production between Treg populations, we detected 
a prominent population of IFN-γ-producing uTregs both in 
HIV-TB and HD groups (Figures 6E–G) that was restricted to 
the CD39neg Treg subset (Figure  6I). Moreover, we observed a 
negative correlation between IFN-γ and FoxP3 expression inten-
sity levels on a per cell basis (Figure 6G), according to a negative 
regulation of IFN-γ loci by the FoxP3 transcription factor as 
described elsewhere (22).
Finally, in order to compare the suppressor capacity of uTreg 
and cTreg, we analyzed their ability to suppress lymphocyte pro-
liferation and cytokine production in vitro. As we observed that 
CD39 expression was highly increased in both uTregs and cTregs 
compared to only 2% of CD25−FoxP3−CD4+ effector T  cells 
expressing the inhibitory molecule (Figure S4 in Supplementary 
Material), we decided to use CD25+CD39+CD4+ as a surrogate 
population for regulatory T  cells in the subsequent functional 
experiments. We thus isolated CD25+CD39+CD4+ T  cells 
FigUre 5 | a distinct effector/memory differentiation path occurs in 
Treg lymphocytes from coinfected patients. Correlation analysis between 
the % of uTregCM and the % of uTregEM and between the % of cTregCM and 
the % of cTregEM from (a,c) HIV-TB and (B,D) healthy donors (HD) individuals 
in order to infer recent effector/memory transitions as described previously 
(13). Spearman rank test was used for the evaluation of the correlation. 
p < 0.05 was considered significant.
FigUre 4 | continued  
Differing maturation status of uTreg and cTreg in hiV-TB and  
healthy donors (hD) individuals. Evaluation of effector/memory  
phenotype distribution between uTreg and cTreg in HIV-TB (upper panel) and 
healthy donors (HD) (lower panel) individuals. Pie charts summarize the data 
and each slice corresponds to the mean proportion of uTreg or cTreg cells for 
each phenotype. Each point represents a single individual. Comparisons 
between phenotype distributions were performed using the partial 
permutation test follow by Kruskal–Wallis test and the Dunn’s multiple 
comparisons posttest. Asterisks indicate significant difference between 
groups. *p < 0.05; **p < 0.01; ***p < 0.001.
FigUre 4 | continued
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(cTreg), CD25−CD39+CD4+ (uTregs), and CD25−CD39−CD4+ 
(T-cell responder population) by FACS sorting (Figure S4 in 
Supplementary Material). For the assessment of their suppressor 
capacity, CD25−CD39+CD4+ or control CD25+CD39+CD4+ T cells 
from HD were cocultured with responder CD25−CD39−CD4+ 
T cells at different ratios. Therefore, it could be observed that uTregs 
were capable of suppressing the polyclonal-induced proliferation 
of responder T cells by more than 60% when cocultured at a 1:1 
ratio, showing lower inhibitory capacity at higher Treg:effector 
ratios when compared to cTregs (Figure  7A). Moreover, uTreg 
and cTreg cells were analyzed for their capacity to suppress 
IFN-γ production from polyclonally stimulated effector T cells. 
FigUre 6 | uTregs produce a distinct pattern of cytokines and high levels of iFn-γ. PBMC from HIV-TB and healthy donors (HD) were stimulated with  
PMA/Io and analyzed by flow cytometry for the indicated cytokines. Comparison of latency-associated peptide (LAP) expression between uTreg and cTreg from  
(a) HIV-TB and (B) HD persons. Analysis of IL-10 production between uTreg and cTreg from (c) HIV-TB and (D) HD individuals. Evaluation of IFN-γ production in the 
uTreg and cTreg populations from (e) HIV-TB and (F) HD. (g) Correlation analysis between FoxP3 and IFN-γ mean fluorescence intensity (MFI) in Tregs. Wilcoxon 
test was used for statistical analysis. (h) Representative flow cytometry dot plots depicting IFN-γ production from uTregs (left) and cTregs (right). (i) Representative 
flow cytometry graphs showing IFN-γ production from CD39+ uTregs (left) and CD39− uTregs (right). Each point represents an individual subject. Asterisks indicate 
significant differences between groups. *p < 0.05; ***p < 0.001. Spearman test was performed for correlation analysis.
9
Angerami et al. Treg Differentiation in HIV-TB
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 528
Thus, as observed for the proliferative cell’s competence, a signifi-
cant suppression of cytokine production capacity was achieved by 
both uTregs and cTregs from HD (Figure 7B). Notably, although 
only near 50% of CD25−CD39+CD4+ T  cells were Foxp3+, 
their suppressor capacity was similar to that appreciated on 
CD25+CD39+CD4+ Tregs, which depicted 90% of Foxp3 expres-
sion (Figure S4 in Supplementary Material). These data strongly 
indicate that “unconventional” Tregs are a Treg population with 
preserved inhibitory capacity, albeit uTregs display a distinct 
phenotype with higher expression of surface CD39 and PD1 and 
a more differentiated memory/effector profile.
DiscUssiOn
Mycobacterium tuberculosis and HIV coinfection entails a sce-
nario where both infections worsen the outcome of each other, 
leading to the progression of both diseases. The relevance of 
Tregs in this context is a matter of continuous study, since Tregs 
are involved in both TB and HIV immune responses (6, 23). In 
TB, Tregs control immunopathology and also are able to down-
modulate effector responses, necessary for pathogen eradication 
(24). Tregs are highly heterogeneous, with differing phenotypes 
besides their FoxP3 expression. Similar to effector T cells, TCR 
activation induces Tregs differentiation resulting in dissimilar 
memory populations (25). In turn, each population has its own 
inhibitory potential, since it has been described that EM Treg 
lymphocytes display a more potent inhibition capacity compared 
to terminal effector or CM cells (13). Moreover, surface proteins 
can also orchestrate Treg function, as CD39 can inhibit T  cell 
effector functions by modulating adenosine concentration (26), 
PD1 can deliver inhibitory signals through PDL1 engagement to 
effector T lymphocytes (18), and GITR can enhance Treg function 
(27). Taking into account our previous observations as a starting 
point, we aimed to study the expanded FoxP3+CD25−CD4+ 
FigUre 7 | Functional characterization of uTregs. FACS-isolated 
CD4+CD25−CD39− effector T cells were stimulated with anti-CD3 plus 
allogeneic mitomycin-treated PBMCs and cocultured with CD4+CD25−CD39+ 
uTregs or CD4+CD25+CD39+ cTregs cells at the indicated Treg:Teff ratios.  
In addition, effector T cells were left unstimulated in order to determine basal 
proliferation. After 5 days, proliferation and IFN-γ secretion were evaluated. 
Proliferation levels of stimulated CD4+CD25−CD39− effector T cells without 
any Treg population were defined as 100%. (a) Proliferation of effector T cells 
at different Teff/Treg ratios. (B) IFN-γ production in cell-free supernatants from 
cocultures was assessed by ELISA. Bars represent mean values + SEM from 
three individual experiments. *p < 0.05.
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population in a cohort of HIV-TB coinfected individuals from 
Argentina. This T  cell population was previously observed in 
the context of SLE (8, 9), raising the question whether these 
cells were activated effector T  cells transiently expressing the 
transcription factor FoxP3 or were abnormally differentiated 
Tregs with impaired regulatory functions. We observed that 
this unique population depicted similarities in their memory/
effector status compared to FoxP3+CD25+CD4+ “conventional” 
Tregs, but had some differences regarding CD39 and PD1 expres-
sion. Interestingly, this uTreg population exerted a huge ability 
to secrete IFN-γ, while it could efficiently inhibit effector T cell 
responses. IFN-γ-producing FoxP3+ Tregs were detected in the 
context of graft-versus-host disease, in Listeria monocytogenes 
infection in mice (28) and also in human autoimmune disease 
(29). This uTreg expansion could be probably induced by TB, since 
we observed that after TB treatment uTreg levels reached normal 
ranges on peripheral blood from HIV-TB patients. Furthermore, 
patients’ immune status was related with this expansion, since 
uTregs frequency negatively correlated with CD4+ T cell count in 
HIV-TB patients and positively correlated with PD1 expression 
in CD4+ T cells. These results could be related to the data showed 
by Amarnath and colleagues indicating a role for PD1–PDL1 axis 
on the differentiation of Th1  cells into regulatory T  cells (30). 
Our results also indicate that the maturation status of T cells is 
related to uTreg expansion, since EM CD4+ T cells percentages 
(which are the main effector populations against the pathogen) 
negatively correlated with uTreg proportions, therefore suggest-
ing a bias to a less differentiated phenotype for effector T cells in 
an scenario where uTregs could be inhibiting anti-mycobacterial 
responses.
Maturation status can define the functional capacity of a 
given cell population, as described for Tregs and conventional 
T  cells (13, 31). We observed that uTreg from coinfected 
individuals exhibited a more differentiated phenotype with an 
expansion of the highly suppressor TregEM subset (13), prob-
ably resulting in diminished antitubercular immune responses 
at the site of infection. Our studies on the characterization of 
uTregs showed that these cells had phenotypic differences from 
cTregs, and these differences became more noticeable during 
HIV-TB coinfection. CD39, a Treg-associated ectonuclease, 
acts hydrolyzing ATP or ADP into AMP, thereby generating an 
anti-inflammatory environment (26). Thus, a lower expression 
of CD39 on the surface of uTreg (as shown in Figure 3) could 
be related to a defective ability to control immune responses. 
Furthermore, the expression of PD1, a molecule associated with 
T cell exhaustion in the context of chronic infections such as HIV 
(32) was augmented on uTreg compared to cTreg, therefore sug-
gesting an exhausted phenotype for this population. However, a 
recent study from Park et al. has described an active role of PD1 
(present on the surface of LTreg) in the inhibition of LT CD8+ 
responses to a chronic viral infection, where interaction with 
PDL1 on the surface of CD8+ T lymphocytes actively inhibited 
the effector function of these cells (18). Therefore, an increased 
expression of PD1 on the surface of uTreg would result in an 
increased inhibitory capacity, contrary to the former governing 
paradigm.
On the other hand, little progress has been made on the 
study of the effect of signaling GITR in Treg. However, it has 
been recently described that signaling through GITR induces 
an increase in the proliferation of Treg lymphocytes in vitro and 
in  vivo (33). Therefore, intracellular signaling of GITR could 
be a stimulus of cellular activation, increasing the regulatory 
capacity of Tregs. Therefore, in view of a phenotype showing 
a low expression of CD39 concomitantly with high levels of 
PD1 and GITR on the surface of uTreg from HIV-TB patients, a 
possible scenario could be that this population could retain its 
ability to modulate T cell responses through increased expres-
sion of PD1 and GITR. Conversely, this modulating capacity 
would be compromised due to the low expression of CD39 
and high expression of PD1, showing an exhausted phenotype 
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for these unconventional regulatory cells. A third possibility 
could be that this unique population acquires novel strategies 
for inhibition of T cell responses, as described for LES, where 
CD25− Tregs could inhibit T  cell proliferation but not IFN-γ 
production (8). We addressed this question by studying the 
inhibitory capacity of uTregs in an in vitro setting and found that 
uTreg cells have the ability to suppress proliferation and IFN-γ 
production of effector lymphocytes to an extent comparable to 
cTreg (Figure 7).
The ability to modulate the responses from LTreg involves 
several mechanisms, such as the secretion of modulatory cytoki-
nes like IL-10 or TGF-β (34–36). Our results show a similar ability 
to produce and secrete IL-10 and TGF-β by conventional and 
unconventional Treg populations, therefore indicating that their 
modulatory capacity through soluble mediators would be com-
parable. Remarkably, uTregs from coinfected patients depicted 
high levels of IFN-γ production compared to cTregs. This ability 
for IFN-γ secretion by CD4+CD25−FoxP3+ cells was previously 
shown by Yang in the context of lupus patients (9). Nevertheless, 
the levels of IFN-γ observed by these authors were much lesser 
than our observations perhaps due to the gating strategy they 
used based on CD127 expression (9). These authors also ana-
lyzed the ability of uTreg cells to inhibit effector T lymphocytes 
responses. Unfortunately, they used CD127 as a surrogate mark er 
for Treg isolation, obtaining a CD4+CD25−CD127 low/neg 
population with a very low proportion of FoxP3 [around 9% (9)], 
therefore achieving inconclusive results. On the other hand, 
Bonelli obtained around 53% of CD4+CD25−CD127− T  cells, 
which inhibited T cell proliferation but not IFN-γ production (8). 
A possible explanation for this finding is that Bonelli’s Tregs could 
encompass IFN-γ producers, a population that was not investi-
gated in that work (8). Thus, Yang’s and Bonelli’s works provide 
evidence supporting the existence of a regulatory subpopulation 
with the capacity for IFN-γ production which was not observed 
in other scenarios beyond SLE or in the present study focused on 
HIV-TB coinfection.
Finally, we provide evidence regarding the pathogenesis of TB 
in the context of HIV infection, describing a unique population 
of regulatory T  cells which may arise from a preexisting pool 
that is expanded under the inflammatory milieu generated by 
coinfection. This population, described previously only during 
another inflammatory disease such as autoimmune LES, may 
be involved in the pathogenic mechanisms developed during 
HIV-TB coinfection. Our results show for the first time an in-
depth analysis of unconventional CD25− Tregs that may provide 
significant information in order to generate novel approaches 
for a better management of Mtb infection in patients coinfected 
with HIV.
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